当前位置: X-MOL 学术J. Urol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Four versus Three Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathologic Response and Survival.
The Journal of Urology ( IF 5.9 ) Pub Date : 2021-08-27 , DOI: 10.1097/ju.0000000000002189
Hiten D Patel 1 , Sunil H Patel 2 , Enrique Blanco-Martinez 1 , Jake Kuzbel 2 , Victor S Chen , Aleksander Druck 1 , Elizabeth L Koehne 1 , Parth M Patel 1 , Chirag P Doshi 1 , Noah M Hahn 2, 3 , Jean H Hoffman-Censits 2, 3 , Stephanie Berg 4 , Trinity J Bivalacqua 2 , Max Kates 2 , Marcus L Quek 1
Affiliation  

Ideal number of neoadjuvant chemotherapy (NAC) cycles for muscle-invasive bladder cancer is uncertain with 3 to 4 representing the standard of care (SOC). We compared ypT0 rates and survival between patients receiving 4 versus 3 cycles of NAC with evaluation of chemotherapy-related toxicity for correlation with tumor chemosensitivity and pathologic response.

中文翻译:

肌肉浸润性膀胱癌新辅助化疗的四个与三个周期:对病理反应和生存的影响。

肌肉浸润性膀胱癌的理想新辅助化疗 (NAC) 周期数尚不确定,3 至 4 代表护理标准 (SOC)。我们比较了接受 4 和 3 周期 NAC 的患者之间的 ypT0 率和生存率,并评估了化疗相关毒性与肿瘤化学敏感性和病理反应的相关性。
更新日期:2021-08-27
down
wechat
bug